Cytological Assessment of Donor-Site Healing After Free Gingival Grafting

November 8, 2026 updated by: Ayse Ege SELMAN, Biruni University

Cytological Evaluation of the Effects of Different Donor-Site Interventions on Healing After Free Gingival Graft Surgery

An adequate width of keratinized gingiva is important for maintaining periodontal and peri-implant tissue health. Free gingival grafting (FGG) is a commonly performed surgical procedure for increasing insufficient keratinized gingival width. This study aims to evaluate the effect of applying a chitosan sponge to the palatal donor site on wound healing after FGG using exfoliative cytology and to compare the findings with those obtained from a control group in which no chitosan sponge is applied.

At least 40 patients scheduled to undergo FGG because of insufficient keratinized gingival width will be included. The patients will be allocated to two groups: a test group and a control group. In the test group, a chitosan sponge will be applied to the palatal donor site, whereas no wound dressing will be applied to the palatal donor site in the control group. The primary outcome will be the keratinization index determined from cytological samples collected from the palatal donor site at one month after surgery. The keratinization index values at one month will be compared between the test and control groups.

All participants will receive detailed information about the study and the procedures, and written informed consent will be obtained. Clinical measurements will be recorded before surgery, after which the FGG procedure will be performed. Depending on group allocation, the palatal donor site will either be treated with a chitosan sponge or left without a wound dressing. Sutures will be removed on postoperative day 10.

For exfoliative cytological assessment, baseline samples will be collected from both the planned palatal donor site and the contralateral symmetrical healthy palatal site, which will not undergo surgery, in all patients. Samples collected from the symmetrical palatal site will serve as a reference for the baseline characteristics of healthy palatal mucosa. Follow-up samples will be collected exclusively from the palatal donor site on postoperative day 3,10 and at 1, 3, and 6 months. The keratinization index and other cellular features associated with wound healing will be assessed in the cytological samples. Findings obtained during the follow-up periods will be compared between the test group treated with a chitosan sponge and the control group in which no wound dressing is applied. In addition, the presence or absence of sensory loss at the palatal donor site will be evaluated using a periodontal probe.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Volunteering to participate in the study,
  • Being at least 18 years of age,
  • The need for SDG in patients with < 2 mm of keratinized gingiva on the vestibular side of the implant/tooth,
  • No prior surgical procedures or grafts in the palatal region,Volunteering to participate in the study,

Exclusion Criteria:

  • The presence of a systemic disease that would contraindicate surgical treatment,
  • Uncontrolled diabetes (HbA1c > 7),
  • Pregnancy or breastfeeding,
  • Autoimmune and/or inflammatory diseases of the oral cavity,
  • Active periodontal disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control

Free gingival graft surgery

Experimental: Test

Free gingival graft surgery

Suturing of chitosan sponge to the palatal donor site

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Palatal donor site tissue thickness:
Time Frame: Pre-operative

The thickness of the donor site will be measured using an endodontic reamer.

Pre-operative
Palatal donor site tissue thickness:
Time Frame: immediate Post-operative

The thickness of the donor site will be measured using an endodontic reamer.

immediate Post-operative
Palatal donor site tissue thickness:
Time Frame: day 10

The thickness of the donor site will be measured using an endodontic reamer.

day 10
Palatal donor site tissue thickness:
Time Frame: day 30

The thickness of the donor site will be measured using an endodontic reamer.

day 30
Palatal donor site tissue thickness:
Time Frame: day 90

The thickness of the donor site will be measured using an endodontic reamer.

day 90
Palatal donor site tissue thickness:
Time Frame: day 180

The thickness of the donor site will be measured using an endodontic reamer.

day 180
Keratinization Index
Time Frame: day 3

Cells without nuclei / Total number of cells examined (n=200) × 100

day 3
Keratinization Index
Time Frame: day 10

Cells without nuclei / Total number of cells examined (n=200) × 100

day 10
Keratinization Index
Time Frame: day 30

Cells without nuclei / Total number of cells examined (n=200) × 100

day 30
Keratinization Index
Time Frame: day 90

Cells without nuclei / Total number of cells examined (n=200) × 100

day 90
Keratinization Index
Time Frame: day 180

Cells without nuclei / Total number of cells examined (n=200) × 100

day 180
Superficial cell index
Time Frame: day 3

Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

day 3
Superficial cell index
Time Frame: day 10

Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

day 10
Superficial cell index
Time Frame: day 30

Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

day 30
Superficial cell index
Time Frame: day 90

Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

day 90
Superficial cell index
Time Frame: day 180

Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

day 180

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Loss of sensation
Time Frame: Day 10

To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

Day 10
Loss of sensation
Time Frame: Day 30

To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

Day 30
Loss of sensation
Time Frame: Day 90

To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

Day 90
Loss of sensation
Time Frame: Day 180

To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

Day 180

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2026

Primary Completion (Estimated)

November 30, 2026

Study Completion (Estimated)

December 30, 2026

Study Registration Dates

First Submitted

November 8, 2026

First Submitted That Met QC Criteria

November 8, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 8, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2015-KAEK-80-23-44

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe